See more : Ferrovial, S.A. (0P2N.L) Income Statement Analysis – Financial Results
Complete financial analysis of BioLineRx Ltd. (BLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLineRx Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Simbhaoli Sugars Limited (SIMBHALS.NS) Income Statement Analysis – Financial Results
- Genfit S.A. (GNFT.PA) Income Statement Analysis – Financial Results
- Emlak Konut Gayrimenkul Yatirim Ortakligi A.S. (EKGYO.IS) Income Statement Analysis – Financial Results
- CKD Bio Corp. (063160.KS) Income Statement Analysis – Financial Results
- TGC Ventures International, Inc. (TGVN) Income Statement Analysis – Financial Results
BioLineRx Ltd. (BLRX)
About BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.16M | 113.16M | 63.91M | 31.89M |
| Cost of Revenue | 3.69M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 440.89K | 0.00 | 0.00 | 0.00 | 22.62M | 7.21M |
| Gross Profit | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | -451.00K | -480.68K | -481.89K | -440.89K | 0.00 | 113.16M | 113.16M | 41.29M | 24.69M |
| Gross Profit Ratio | 23.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 64.60% | 77.40% |
| Research & Development | 12.52M | 17.63M | 19.47M | 18.17M | 23.44M | 19.81M | 19.51M | 11.18M | 11.49M | 10.90M | 12.65M | 17.21M | 11.20M | 15.49M |
| General & Administrative | 16.64M | 5.07M | 4.27M | 3.84M | 3.74M | 4.41M | 4.04M | 3.95M | 3.65M | 3.49M | 3.68M | 3.71M | 3.34M | 4.14M |
| Selling & Marketing | 14.59M | 6.46M | 1.00M | 840.00K | 857.00K | 1.36M | 1.69M | 1.35M | 1.00M | 1.46M | 1.18M | 863.77K | 869.15K | 1.30M |
| SG&A | 31.23M | 11.53M | 5.27M | 4.68M | 4.60M | 5.77M | 5.73M | 5.31M | 4.65M | 4.95M | 4.86M | 4.57M | 4.21M | 5.44M |
| Other Expenses | 7.05M | 5.67M | 42.00K | 70.00K | 78.00K | 27.00K | -260.00K | 7.00K | 153.00K | 2.81M | -280.83K | -322.27K | 0.00 | 50.17K |
| Operating Expenses | 50.80M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 20.98M |
| Cost & Expenses | 54.49M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 28.19M |
| Interest Income | 2.01M | 694.00K | 559.00K | 236.00K | 777.00K | 719.00K | 1.17M | 480.00K | 457.00K | 3.28M | 746.59K | 2.36M | 3.34M | 861.33K |
| Interest Expense | 2.17M | 2.16M | 984.00K | 1.47M | 1.83M | 21.00K | 21.00K | 14.00K | 15.00K | 411.67K | 20.67K | 25.96K | 1.12M | 16.63K |
| Depreciation & Amortization | 1.38M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 441.00K | 246.54K | 329.36K | 407.93K | 410.67K | 511.28K |
| EBITDA | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | -25.15M | -23.83M | -15.34M | -13.94M | -10.79M | -16.70M | -19.38M | -13.59M | 4.21M |
| EBITDA Ratio | -1,188.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.88% | -18.90% | -23.47% | 20.90% |
| Operating Income | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | -25.61M | -25.24M | -16.51M | -16.20M | -15.85M | -17.63M | -21.83M | -15.41M | 3.70M |
| Operating Income Ratio | -1,035.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.58% | -19.29% | -24.11% | 11.61% |
| Total Other Income/Expenses | -10.92M | 4.21M | -2.28M | -7.09M | 2.67M | 2.64M | 888.00K | 672.00K | 1.80M | 6.18M | -13.16K | 1.37M | 1.39M | -1.61M |
| Income Before Tax | -60.61M | -24.95M | -27.05M | -30.02M | -25.45M | -22.96M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | 61.52M | 2.10M |
| Income Before Tax Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | 96.26% | 6.57% |
| Income Tax Expense | 1.00K | -6.08M | 1.09M | 911.00K | 1.36M | -4.46M | -888.00K | -672.00K | -1.80M | -5.68M | 15.79K | -1.42M | -2.22M | 1.61M |
| Net Income | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M | -18.51M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | -13.19M | 2.10M |
| Net Income Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | -20.63% | 6.57% |
| EPS | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| EPS Diluted | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| Weighted Avg Shares Out | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 823.41K |
| Weighted Avg Shares Out (Dil) | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 830.31K |
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for...
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with the...
Turning Point Solid Tumor Data, And Other News: The Good, Bad And Ugly Of Biopharma
Turning Point reports positive data for tumor drug candidate. BioMarin faces setback for Hemophilia A therapy.
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2020 Results - Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q1 2020 Earnings Conference Call May 20, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advis
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received...
BioLineRx to Report Third Quarter 2015 Results on November 16, 2015
TEL AVIV, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the third quarter ended September 30, 2015 on...
BioLineRx to Report Second Quarter 2015 Results on August 20, 2015
TEL AVIV, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2015 on...
BioLineRx to Report First Quarter 2015 Results on May 18, 2015
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended March 31, 2015 on Monday, May...
BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2014 on Monday,...
BioLineRx and Major Global Pharmaceutical Company Form Strategic Collaboration for Screening and Development of Novel Drug Candidates
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has entered into a multi-year strategic collaboration agreement with Novartis Pharma AG designed to facilitate development...
Source: https://incomestatements.info
Category: Stock Reports